Overview
Over the last few years, chimeric antigen receptor (CAR) T-cell therapy emerged as a new form of immunotherapy. Novel CAR designs coupled with advances in gene transfer technology and gene editing has opened the door for new cancer therapies. However, there are still many challenges that needs to be tackled to accelerate development.
CARs consist of a extracellular binding domain, a hinge region, a transmembrane domian, and one or more intracellular domains. Fine-tuning each domain of the CAR is one of the initial steps to improving T cell specificity, antigen recognition, and T cell function. Studies have shown that small modifications to the CAR can have significant impact on the therapeutic outcome. Therefore, it key to have a comprehensive library to interrogate as each CAR construct needs intensive testing.
Twist has developed a technology to build CAR libraries in a manner that seamlessly shuffles variants of each domain via scarless assembly process.
How does it work?
Figure1: Each of these domains can consist of several different sequence variants. These domains are synthesized as genes which Twist combines together in a through scarless assembly process to generate a highly diverse library for scaffold optimization. This technology enables the discovery of unique domain combinations that reveal novel functionalities.
Chimeric Antigen Receptor (CAR) Discovery and Optimization Workflow
Each domain of the CAR scaffold influences the functionality of the CAR both independently and synergistically. CAR Libraries serve as a tool to fine-tune each of the modules to uncover codependencies and better understand the impact on T-cell specificity, antigen recognition and T-cell function.
Partner with Twist at any stage of your discovery workflow!
- Leverage both in vivo and in vitro workflows for binder discovery and optimization
- Leverage our synthetic libraries for scaffold optimization and validation
Tell us what you would like more information on. We’re here to help!
Contact Us
Overview
Over the last few years, chimeric antigen receptor (CAR) T-cell therapy emerged as a new form of immunotherapy. Novel CAR designs coupled with advances in gene transfer technology and gene editing has opened the door for new cancer therapies. However, there are still many challenges that needs to be tackled to accelerate development.
CARs consist of a extracellular binding domain, a hinge region, a transmembrane domian, and one or more intracellular domains. Fine-tuning each domain of the CAR is one of the initial steps to improving T cell specificity, antigen recognition, and T cell function. Studies have shown that small modifications to the CAR can have significant impact on the therapeutic outcome. Therefore, it key to have a comprehensive library to interrogate as each CAR construct needs intensive testing.
Twist has developed a technology to build CAR libraries in a manner that seamlessly shuffles variants of each domain via scarless assembly process.
How does it work?
Figure1: Each of these domains can consist of several different sequence variants. These domains are synthesized as genes which Twist combines together in a through scarless assembly process to generate a highly diverse library for scaffold optimization. This technology enables the discovery of unique domain combinations that reveal novel functionalities.
Chimeric Antigen Receptor (CAR) Discovery and Optimization Workflow
Each domain of the CAR scaffold influences the functionality of the CAR both independently and synergistically. CAR Libraries serve as a tool to fine-tune each of the modules to uncover codependencies and better understand the impact on T-cell specificity, antigen recognition and T-cell function.
Partner with Twist at any stage of your discovery workflow!
- Leverage both in vivo and in vitro workflows for binder discovery and optimization
- Leverage our synthetic libraries for scaffold optimization and validation
Tell us what you would like more information on. We’re here to help!
Contact Us
Let's Get Started
- Step 1: Complete the contact details form on this page
- Step 2: Download the CAR Submission Form and fill out all fields in the form for your library design
- Step 3: Upload the completed submission form to the "Submit File" tab on this page
Ready to Submit?
- Step 1: Upload completed submission form
- Step 2: Our Library Team Experts will review your project
- Step 3: Library Team verifies the project and will reach out to you with a quote
- Step 4: Once the quote is accepted by the customer, Library Team will send the project to the production team
If you have any questions, please feel free to email us at [email protected]
Let's Get Started
- Step 1: Complete the contact details form on this page
- Step 2: Download the CAR Submission Form and fill out all fields in the form for your library design
- Step 3: Upload the completed submission form to the "Submit File" tab on this page
Ready to Submit?
- Step 1: Upload completed submission form
- Step 2: Our Library Team Experts will review your project
- Step 3: Library Team verifies the project and will reach out to you with a quote
- Step 4: Once the quote is accepted by the customer, Library Team will send the project to the production team
If you have any questions, please feel free to email us at [email protected]
Performance Data
CAR-T cell therapies are a promising approach for treating solid tumors. But identifying appropriate T-Cell receptor (TCR) domains that exclusively target tumor antigens remains a challenge. Toxicity, tumor activation, and tumor persistence are significant challenges to using CAR-T cell therapies for solid tumors. Here you can see how Serotiny used Twist’s Combinatorial Assembly Libraries to design and evaluate thousands of CARs, each with novel intracellular signaling architectures. By using these libraries, Serotiny rapidly selected multiple novel CAR designs to enhance the therapeutic performance of primary T-cells.
Performance Data
CAR-T cell therapies are a promising approach for treating solid tumors. But identifying appropriate T-Cell receptor (TCR) domains that exclusively target tumor antigens remains a challenge. Toxicity, tumor activation, and tumor persistence are significant challenges to using CAR-T cell therapies for solid tumors. Here you can see how Serotiny used Twist’s Combinatorial Assembly Libraries to design and evaluate thousands of CARs, each with novel intracellular signaling architectures. By using these libraries, Serotiny rapidly selected multiple novel CAR designs to enhance the therapeutic performance of primary T-cells.
